Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

bluebird bio

Bluebird Bio's most recently approved gene editing therapy looks highly promising. Novavax has generated decent revenue from its coronavirus vaccine.

Better Buy: Bluebird Bio Vs. Novavax

Novavax's business still centers heavily around COVID-19. This year, it expects up to $1 billion in revenue.

Down 60% From Its 52-Week High, Is Novavax Stock a Buy?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

Blink Charging

Cardiff Oncology

Hive Blockchain Technologies Ltd

Riot Blockchain

Vaxart

The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That's because it looks to be a rematch between President Biden and former President Trump.

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

Teladoc

Teladoc's position in the growing telemedicine industry could help it turn things around. Novavax's only approved product is going nowhere and its pipeline has too little to offer.

1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024.

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.

This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery

Novavax's coronavirus franchise isn't performing well. The company has no other product close to approval.

1 Beaten-Down Stock That's Still Not Worth Buying

Biomea Fusion Inc

BioXcel Therapeutics

Guess?

MicroCloud Hologram Inc

RumbleON

Tupperware

There's a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they're intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy.

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

Ocugen, Inc.

Novavax and Ocugen were early contenders in the coronavirus vaccine race -- but didn't meet investors' expectations in that market. As a result, shares of both companies have plummeted.

Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street

Imperial Petroleum

Big GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) may have lost investor focus, but these meme stocks keep interests high. Of the many indicators aiding to time the market, short interest remains the most popular.

The Short List: 3 Meme Stock Battlegrounds to Keep on Your Radar

Novavax, Inc. (NASDAQ:NVAX ) TD Cowen's 44th Annual Health Care Conference Call March 6, 2024 1:30 PM ET Company Participants John Jacobs - President and Chief Executive Officer Filip Dubovsky - President, Research and Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Brendan Smith - TD Cowen Brendan Smith All right. I think it's about 1:30, so we'll get started.

Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference - (Transcript)

Ironwood Pharma

Moderna

Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, treatment authorization, or any number of events that could be or break a company.

It's Time! 3 Failing Biotech Stocks to Sell Right Now

GameStop

Throughout the history of financial markets, there is ample evidence of irrational investor behavior leading to euphoria. Be it the Tulip Mania of 1634 or the Housing Bubble and the subsequent financial crisis, markets tend to react on the extremes.

Exit Alert: 3 Overhyped Stocks With Weak Fundamentals

Novavax has reported both positive and negative news in recent days, sending the shares higher, then lower. The company settled a dispute with a key customer, but quarterly earnings missed analysts' estimates.

Is Novavax a Buy Now?

In 2022, Novavax canceled a purchase agreement with Gavi, leading to a dispute over $700 million in advance payments. A settlement has been reached, and Novavax may only pay up to $475 million back to Gavi.

1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?

GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference

Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.

Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks

Novavax, Inc. (NASDAQ:NVAX) shares fell over 27% on Wednesday as the Covid-19 vaccine maker warned of slowing sales ahead after missing earnings expectations in the final quarter. Revenue for the three months to December fell over 18% to US$291.3 million, the firm said on Wednesday, with analysts having expected the figure to sit at US$322 million, as per LSEG data.

Novavax sheds a quarter of value as sales look to remain pressured

The headline numbers for Novavax (NVAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Novavax (NVAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Novavax, Inc. (NASDAQ:NVAX) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET

Novavax, Inc. (NVAX) Q4 2023 Earnings Call Transcript

Novavax Inc (NASDAQ:NVAX) missed  top- and bottom-line estimates  for the fourth quarter.

Novavax Stock on Track for Worst Day Since 2022

Novavax (NASDAQ:NVAX) stock is falling hard on Wednesday as investors react to the vaccine company's earnings report for the fourth quarter of 2024. Let's dig into everything that has investors in NVAX stock disappointed today below!

NVAX Stock Alert: 9 Reasons Why Novavax Investors Are So Disappointed Today

Novavax (NVAX) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $2.28 per share a year ago.

Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates

Novavax posts a fourth-quarter loss of $1.44 a share on revenue of $291.3 million.

News for Novavax Stock (NVAX)